Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RCUS

Arcus Biosciences Inc

Nov 12 • 04:00PM ET

20.00

-0.29 -1.43 %

Healthcare • Biotechnology • USA • NYSE

Peers: BMY MRK PFE JNJ GILD ABBV NVS LLY REGN VRTX

| Held by: IJR IWM VTI XBI SPSM IJT VXF VB IWO IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.43	Insider Own	38.70%	Shs Outstand	107.10M	Perf Week	1.27%
Market Cap	2.47B	Forward P/E	-	EPS next Y	-4.09	Insider Trans	-0.44%	Shs Float	75.84M	Perf Month	28.04%
Enterprise Value	1.75B	PEG	-	EPS next Q	-1.16	Inst Own	54.20%	Short Float	11.00%	Perf Quarter	101.82%
Income	-341.00M	P/S	10.31	EPS this Y	-16.12%	Inst Trans	-0.80%	Short Ratio	6.88	Perf Half Y	134.19%
Sales	240.00M	P/B	4.91	EPS next Y	-12.29%	ROA	-30.64%	Short Interest	8.34M	Perf YTD	34.32%
Book/sh	4.07	P/C	2.98	EPS next 5Y	-1.82%	ROE	-68.13%	52W High	22.11 -9.54%	Perf Year	12.04%
Cash/sh	6.72	P/FCF	-	EPS past 3/5Y	- -10.20%	ROIC	-63.86%	52W Low	6.50 207.69%	Perf 3Y	-12.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.33% 76.65%	Gross Margin	95.83%	Volatility	5.06% 6.85%	Perf 5Y	-4.40%
Dividend TTM	-	EV/Sales	7.31	EPS Y/Y TTM	-8.79%	Oper. Margin	-156.25%	ATR (14)	1.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.65	Sales Y/Y TTM	-8.75%	Profit Margin	-142.08%	RSI (14)	65.80	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	3.65	EPS Q/Q	-25.93%	SMA20	6.18%	Beta	0.77	Target Price	34.20
Payout	-	Debt/Eq	0.25	Sales Q/Q	-45.83%	SMA50	29.81%	Rel Volume	1.36	Prev Close	20.29
Employees	627	LT Debt/Eq	0.22	Earnings	Oct 28 AMC	SMA200	82.66%	Avg Volume	1.21M	Price	20.00
IPO	Mar 15, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.05% 23.81%	Trades		Volume	1,655,359	Change	-1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy	$18 → $24
Oct-21-24	Initiated	H.C. Wainwright	Neutral	$20
Oct-08-24	Initiated	Wells Fargo	Overweight	$29
Nov-18-22	Initiated	BofA Securities	Neutral	$33
Oct-11-22	Initiated	Morgan Stanley	Overweight	$40
Oct-15-21	Resumed	BTIG Research	Buy	$57
Nov-24-20	Initiated	Berenberg	Buy	$50
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-04-20	Initiated	Barclays	Overweight	$24
Nov-12-19	Initiated	SunTrust	Buy	$20
Sep-27-19	Initiated	Mizuho	Buy	$22
May-24-19	Resumed	Citigroup	Buy	$25
Oct-09-18	Initiated	Wedbush	Outperform	$22
Apr-09-18	Initiated	Leerink Partners	Outperform	$21
Apr-09-18	Initiated	Goldman	Neutral	$18
Apr-09-18	Initiated	Citigroup	Buy	$18

Show Previous Ratings

Oct-30-25 11:35PM	Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock (Business Wire)
04:01PM	Arcus Biosciences Announces Commencement of Public Offering of Common Stock (Business Wire)
Oct-28-25 05:55PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +6.88%
04:05PM	Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
05:23AM	Arcus Biosciences (RCUS) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
06:16AM	Loading…
Oct-26-25 06:16AM	Arcus Biosciences Inc. (RCUS) Posts Positive Results on Kidney Cancer Drug Trials (Insider Monkey)
Oct-19-25 07:00PM	Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia (Business Wire)
Oct-12-25 06:05PM	Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study (Business Wire)
Oct-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Oct-07-25 04:04PM	How Arcus Biosciences Aims To Take On Merck In Cancer Treatment (Investor's Business Daily) +7.27%
09:40AM	Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-06-25 08:00AM	Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event (Business Wire) +8.46%
Sep-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Sep-08-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -6.15%
Sep-02-25 04:05PM	Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation (Business Wire) +7.68%
04:05PM	Loading…
Aug-20-25 04:05PM	Arcus Biosciences to Participate in Three Upcoming Investor Conferences (Business Wire)
Aug-15-25 10:07PM	Jim Cramer on Arcus Biosciences: "Let This Be Your Speculation" (Insider Monkey)
Aug-13-25 08:56PM	Lightning Round: Arcus Biosciences is speculative, it's too risky to fully bank on, says Jim Cramer (CNBC TV)
Aug-06-25 06:10PM	Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
Aug-05-25 05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
Jul-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jul-10-25 08:30AM	Arcus Biosciences Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer (Business Wire)
Jul-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +9.76%
Jul-01-25 02:42AM	Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment (Insider Monkey)
Jun-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jun-10-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -9.38%
Jun-01-25 10:45AM	Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response (Business Wire)
May-27-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
May-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +6.28%
10:14AM	Loading…
May-07-25 10:14AM	Q1 2025 Arcus Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:21AM	Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.17%
04:05PM	Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update (Business Wire)
May-05-25 09:56AM	Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result (GuruFocus.com)
Apr-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Apr-23-25 04:05PM	Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire)
Apr-22-25 04:05PM	Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update (Business Wire)
Apr-09-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) +12.78% -5.54%
Apr-02-25 03:48PM	Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts (Seeking Alpha)
Mar-25-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -7.89%
Mar-14-25 11:25AM	Arcus Biosciences, Inc. (RCUS): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:45PM	Arcus Biosciences (RCUS): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-26-25 04:35PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Feb-25-25 06:00PM	Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update (Business Wire)
01:38AM	Arcus Biosciences Inc (RCUS) Q4 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Feb-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -8.22%
Feb-18-25 08:40AM	Arcus says new data demonstrated best-in-class potential for casdatifan (TipRanks) -16.34%
06:57AM	Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering (Business Wire)
06:52AM	Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock (Business Wire)
Feb-15-25 03:45PM	New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer (Business Wire)
Feb-11-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Feb-10-25 05:00PM	Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium (Business Wire)
Jan-24-25 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jan-21-25 04:05PM	Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer (Business Wire) -5.23%
Dec-24-24 04:05PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Dec-19-24 04:05PM	Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-10-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Dec-03-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Dec-02-24 10:18AM	Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend (PR Newswire)
Nov-19-24 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-12-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -5.52%
Nov-07-24 02:26AM	Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Nov-06-24 05:35PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:22PM	Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update (Business Wire)
Nov-05-24 09:00AM	Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer (Business Wire)
07:48AM	What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 10:01AM	Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:00AM	Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting (Business Wire)
Oct-24-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire) -8.47%
07:30AM	First Clinical Data for Arcus Biosciences HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer (Business Wire)
Oct-22-24 04:05PM	Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update (Business Wire)
Oct-17-24 03:02PM	State Street Corp's Strategic Adjustment in Arcus Biosciences Holdings (GuruFocus.com)
Oct-09-24 06:03PM	Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
08:00AM	Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium (Business Wire)
Oct-02-24 04:05PM	Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma (Business Wire)
Sep-24-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Sep-10-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Aug-28-24 02:33PM	Arcus Biosciences obtains loan facility with Hercules Capital worth $250m (Pharmaceutical Technology)
Aug-27-24 04:05PM	Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital (Business Wire)
Aug-26-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Aug-21-24 04:05PM	Arcus Biosciences to Participate in Two Upcoming Investor Conferences (Business Wire)
Aug-16-24 04:52AM	Nuntius partners with Taiho to develop mRNA cancer therapies (Pharmaceutical Technology)
Aug-08-24 06:15PM	Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.02%
04:05PM	Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update (Business Wire)
Aug-01-24 10:01AM	Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jul-25-24 04:05PM	Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update (Business Wire) +5.54%
Jul-09-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
06:32AM	Taiho exercises option for Arcus Biosciences quemliclustat in Asia (Pharmaceutical Technology)
Jul-08-24 06:00PM	Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia (Business Wire)
Jun-25-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jun-11-24 04:35PM	Arcus Biosciences Announces New Employment Inducement Grants (Business Wire)
Jun-10-24 08:30AM	Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers (Business Wire)
Jun-07-24 10:55AM	Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock? (Zacks)
Jun-06-24 04:05PM	Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-02-24 08:00AM	Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer (Business Wire)
Jun-01-24 08:00AM	Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers (Business Wire)

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jarrett Jennifer	Chief Operating Officer	Nov 07 '25	Option Exercise	1.23	50,291	61,737	264,523	Nov 12 04:04 PM
Jarrett Jennifer	Chief Operating Officer	Nov 07 '25	Sale	18.97	50,291	954,066	214,232	Nov 12 04:04 PM
Jaen Juan C.	President	Oct 30 '25	Sale	20.32	4,314	87,650	1,087,060	Nov 03 04:46 PM
Juan Jaen	Officer	Oct 30 '25	Proposed Sale	20.19	1,173	23,683		Oct 30 06:21 PM
Jaen Juan C.	President	Oct 29 '25	Sale	20.90	77,840	1,626,634	1,091,374	Oct 30 08:49 AM
Jaen Juan C.	President	Oct 28 '25	Sale	20.19	19,019	383,944	1,169,214	Oct 30 08:49 AM
Goeltz II Robert C.	Chief Financial Officer	Oct 28 '25	Sale	20.00	5,000	100,000	92,138	Oct 29 08:54 AM
Robert C. Goeltz II	Officer	Oct 28 '25	Proposed Sale	20.00	5,000	100,000		Oct 28 05:13 PM
Juan Jaen	Officer	Oct 28 '25	Proposed Sale	19.88	100,000	1,988,000		Oct 28 05:09 PM
Jarrett Jennifer	Chief Operating Officer	Oct 08 '25	Option Exercise	1.23	37,792	46,393	252,024	Oct 08 07:08 PM
Jarrett Jennifer	Chief Operating Officer	Oct 06 '25	Option Exercise	1.23	12,500	15,345	226,732	Oct 08 07:08 PM
Jarrett Jennifer	Chief Operating Officer	Oct 08 '25	Sale	15.05	37,792	568,611	214,232	Oct 08 07:08 PM
Jarrett Jennifer	Chief Operating Officer	Oct 06 '25	Sale	14.54	12,500	181,801	214,232	Oct 08 07:08 PM
Jennifer Jarrett	Officer	Oct 06 '25	Proposed Sale	13.35	100,583	1,342,783		Oct 06 04:32 PM
Azoy Alexander	Chief Accounting Officer	Sep 29 '25	Sale	13.00	2,831	36,803	27,363	Sep 30 06:59 PM
ALEXANDER AZOY	Officer	Sep 29 '25	Proposed Sale	12.84	2,831	36,350		Sep 29 04:36 PM
Azoy Alexander	Chief Accounting Officer	Sep 05 '25	Sale	11.88	1,579	18,758	30,194	Sep 05 07:48 PM
ALEXANDER AZOY	Officer	Sep 05 '25	Proposed Sale	11.56	1,579	18,253		Sep 05 04:24 PM
KANEKO YASUNORI	Director	Feb 27 '25	Buy	10.06	20,000	201,200	28,400	Feb 27 07:06 PM
ROSEN TERRY J	Chief Executive Officer	Feb 27 '25	Buy	10.18	19,800	201,465	2,554,160	Feb 27 07:05 PM
GILEAD SCIENCES, INC.	10% Owner	Feb 18 '25	Buy	11.00	1,363,636	14,999,996	31,424,760	Feb 20 07:42 PM
Goeltz II Robert C.	Chief Financial Officer	Dec 31 '24	Sale	15.00	3,594	53,910	60,138	Jan 03 04:08 PM
Goeltz II Robert C.	Officer	Dec 31 '24	Proposed Sale	15.00	3,594	53,910		Dec 31 04:10 PM
Azoy Alexander	Chief Accounting Officer	Dec 02 '24	Sale	15.32	201	3,079	19,070	Dec 04 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RCUS

Arcus Biosciences Inc

Upgrade your FINVIZ experience